17986500

Source:http://linkedlifedata.com/resource/pubmed/id/17986500

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0015980, umls-concept:C0024485, umls-concept:C0026769, umls-concept:C0087111, umls-concept:C0441655, umls-concept:C0475463, umls-concept:C0871261, umls-concept:C1704632, umls-concept:C1706817, umls-concept:C2698872, umls-concept:C2911692
pubmed:issue	6
pubmed:dateCreated	2008-5-19
pubmed:abstractText	To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon beta treatment as response indicators in multiple sclerosis (MS).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/17986500-18487553
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/2985191R
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/interferon beta-1b
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	1468-330X
pubmed:author	pubmed-author:BarberoPP, pubmed-author:BassanoM AMA, pubmed-author:BerguiMM, pubmed-author:ClericoMM, pubmed-author:DurelliLL, pubmed-author:FerreroCC, pubmed-author:GiulianiGG, pubmed-author:Italian Multiple Sclerosis Study Group, pubmed-author:MontanariEE, pubmed-author:PiccoEE, pubmed-author:RipellinoPP, pubmed-author:RivoiroCC, pubmed-author:VerdunEE, pubmed-author:VersinoEE
pubmed:issnType	Electronic
pubmed:volume	79
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	646-51
pubmed:meshHeading	pubmed-meshheading:17986500-Adjuvants, Immunologic, pubmed-meshheading:17986500-Adult, pubmed-meshheading:17986500-Antibodies, pubmed-meshheading:17986500-Brain, pubmed-meshheading:17986500-Drug Administration Schedule, pubmed-meshheading:17986500-Female, pubmed-meshheading:17986500-Follow-Up Studies, pubmed-meshheading:17986500-Humans, pubmed-meshheading:17986500-Injections, Subcutaneous, pubmed-meshheading:17986500-Interferon-beta, pubmed-meshheading:17986500-Magnetic Resonance Imaging, pubmed-meshheading:17986500-Male, pubmed-meshheading:17986500-Middle Aged, pubmed-meshheading:17986500-Multiple Sclerosis, Relapsing-Remitting, pubmed-meshheading:17986500-Neurologic Examination, pubmed-meshheading:17986500-Neutralization Tests, pubmed-meshheading:17986500-Prospective Studies, pubmed-meshheading:17986500-Recombinant Proteins, pubmed-meshheading:17986500-Treatment Outcome
pubmed:year	2008
pubmed:articleTitle	MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis.
pubmed:affiliation	Dipartimento di Scienze Cliniche e Biologiche, Universita' di Torino, Ospedale San Luigi Gonzaga, Regione Gonzole, 10, I-10043 Orbassano, Torino, Italy. luca.durelli@unito.it
pubmed:publicationType	Journal Article, Clinical Trial, Multicenter Study